8-K
filed February 22, 2024, 6:59 PM ET
ticker RCEL
CIK 0001762303
earnings
confidence high
sentiment positive
materiality 0.70
AVITA Medical Q4 commercial revenue up 50% to $14.1M; guides FY2024 rev $78.5-84.5M
AVITA Medical, Inc.
2023-FY EPS reported
$1.40
revenue$50,143,000
- Commercial revenue Q4 $14.1M (+50% YoY); gross margin 87.3%.
- Full-year 2023 commercial revenue $49.8M (+46% YoY); net loss $35.4M ($1.40/share).
- Q1 2024 revenue guidance $14.8-15.6M; FY2024 guidance $78.5-84.5M (57-69% growth).
- Expects RECELL GO FDA launch May 31, 2024; sales team to expand to 108.
- Targeting cashflow breakeven and GAAP profitability no later than Q3 2025.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
AVITA Medical, Inc. reported Fourth Quarter 2023 results: revenue Commercial revenue increased approximately 50% to $14.1 million, EPS Net loss was $7.1 million, or a loss of $0.28 per basic and diluted share.
- Period
- Fourth Quarter 2023
- Revenue
- Commercial revenue increased approximately 50% to $14.1 million
- EPS
- Net loss was $7.1 million, or a loss of $0.28 per basic and diluted share
- Result
- reported results
Exact text from the filing
reported financial results for the fourth quarter and full-year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights • Commercial revenue increased approximately 50% to $14.1 million compared to the same period in 2022 • Gross profit margin of 87.3% Full-Year 2023 Financial Highlights • Commercial revenue increased approximately 46% to $49.8
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
AVITA Medical, Inc. reported first quarter 2024 results: revenue Commercial revenue for the first quarter 2024 is expected to be in the range of $14.8 to $15.6 million. Guidance initiated.
- Period
- first quarter 2024
- Revenue
- Commercial revenue for the first quarter 2024 is expected to be in the range of $14.8 to $15.6 million
- Guidance
- initiated
- Result
- guidance update
Exact text from the filing
Commercial revenue for the first quarter 2024 is expected to be in the range of $14.8 to $15.6 million, reflecting growth of approximately 42% to approximately 50% over the same period in the prior year
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
AVITA Medical, Inc. reported full-year 2024 results: revenue Commercial revenue for the full-year 2024 is expected to be in the range of $78.5 to $84.5 million. Guidance initiated.
- Period
- full-year 2024
- Revenue
- Commercial revenue for the full-year 2024 is expected to be in the range of $78.5 to $84.5 million
- Guidance
- initiated
- Result
- guidance update
Exact text from the filing
Commercial revenue for the full-year 2024 is expected to be in the range of $78.5 to $84.5 million, reflecting growth of approximately 57% to approximately 69% over the full-year 2023
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
AVITA Medical, Inc. reported Full-Year 2023 results: revenue Commercial revenue increased by 46% to $49.8 million, EPS Net loss for the full-year 2023 was $35.4 million, or a loss of $1.40 per basic and diluted share.
- Period
- Full-Year 2023
- Revenue
- Commercial revenue increased by 46% to $49.8 million
- EPS
- Net loss for the full-year 2023 was $35.4 million, or a loss of $1.40 per basic and diluted share
- Result
- reported results
Exact text from the filing
50% to $14.1 million compared to the same period in 2022 • Gross profit margin of 87.3% Full-Year 2023 Financial Highlights • Commercial revenue increased approximately 46% to $49.8 million compared to the same period in 2022 • Gross profit margin of 84.5% • As of December 31, 2023, approximately $89.1 million in cash, cash equivalents, and
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
AVITA Medical, Inc. reported fourth quarter and full-year ended December 31, 2023 results: revenue Commercial revenue increased approximately 50% to $14.1 million, EPS loss of $0.28 per basic and diluted share.
- Period
- fourth quarter and full-year ended December 31, 2023
- Revenue
- Commercial revenue increased approximately 50% to $14.1 million
- EPS
- loss of $0.28 per basic and diluted share
- Result
- reported results
Exact text from the filing
reported financial results for the fourth quarter and full-year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights • Commercial revenue increased approximately 50% to $14.1 million compared to the same period in 2022 • Gross profit margin of 87.3% Full-Year 2023 Financial Highlights • Commercial revenue increased approximately 46% to $49.8
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.